For decades, the pharmaceutical industry’s business model was governed by a predictable rhythm: high-stakes R&D, a blockbuster launch, a period of exclusivity, and—eventually—a "sunset" phase. Once a drug lost its primary patent protection or reached a certain maturity, it was often relegated to the background. These "legacy brands" were treated as passive cash cows, managed for steady, if inevitably declining, revenue with minimal internal investment.
However, the industry is currently facing a "patent cliff" of unprecedented scale. As major pharmaceutical companies scramble to fill looming revenue gaps, the old paradigm of passive management is proving to be a dangerous liability. Today, mature products—those past their peak growth phase—account for 20% to 40% of annual revenue for many top-tier firms. In an era of tightening margins and intense macroeconomic pressure, these assets are no longer just "background noise"; they are vital components of corporate survival.
The Paradigm Shift: From Maintenance to Optimization
The traditional approach to legacy portfolio management—often using infrastructure and talent designed for high-growth, early-stage assets—is fundamentally flawed. Applying high-overhead commercial models to products in their late life cycle is not only inefficient; it actively erodes margins and diverts the attention of top-tier talent away from high-value innovation.
Industry leaders are now recognizing that managing a brand at the end of its life cycle requires a completely different commercial philosophy than that of a new product launch. "Drugs that are late in the product life cycle require a very different approach to commercialization than new launches," says Kirsten Jacobs, Senior Vice President of Regulatory, Compliance, and Pharmacovigilance at Cencora. "Marketing costs should go down, since marketing activities aren’t needed to the same extent as just after launch. Reducing headcount can lower costs. So can centralizing operations."
Chronology of a Shifting Landscape
- 1990s–2010s: The "Set and Forget" Era: Pharmaceutical companies prioritized the next "big thing." Mature products were managed by internal legacy teams, often with bloated processes that were ill-suited to the lower margins of off-patent drugs.
- 2020–2023: The Macroeconomic Wake-up Call: Rising inflation, global supply chain volatility, and the looming expiration of patents for a generation of multi-billion-dollar blockbusters forced CFOs to look at their balance sheets. The realization dawned that "maintenance" was costing too much.
- 2024–2025: The Rise of Strategic Outsourcing: Companies began shifting regulatory, quality, and pharmacovigilance functions to specialized partners. The goal moved from mere "upkeep" to "value capture," with a focus on streamlining operations to protect the bottom line.
Supporting Data: The Cost of Inaction
The numbers underscore the urgency. When a company fails to optimize its mature portfolio, the "hidden" costs of internal management—including excessive Selling, General, and Administrative (SG&A) expenses—quickly accumulate.
Consider the case of a top-20 multinational biopharmaceutical company that recently underwent a radical rebalancing. Faced with the need to protect the availability of mature products for patients while reallocating its most talented internal regulatory affairs experts to new brand development, the firm opted for an outsourced post-approval regulatory model.
"By turning to us for outsourced post-approval regulatory services, delivered by a team of more than 150 dedicated specialists, the program had reduced the company’s internal workload by 20% by the end of its second year," explains Stephan Hütter, Director of Global Client Engagement at Cencora.
This 20% reduction represents more than just labor hours; it represents the liberation of human capital. By outsourcing the "routine maintenance" of pharmacovigilance and regulatory compliance, companies can pivot their internal teams toward R&D, clinical trial management, and next-generation product development.
The Complexity of Global Compliance
Managing legacy portfolios is not merely a matter of cost-cutting; it is a massive logistical challenge. A typical portfolio spans dozens of markets, each with its own idiosyncratic regulatory requirements, labeling laws, and safety reporting protocols.
In the European market, for example, the landscape has grown significantly more complex. Health Technology Assessment (HTA) bodies are increasingly demanding rigorous evidence of both clinical and economic value even for off-patent, mature products. Companies that lack a dedicated, localized presence in these markets often find themselves at a disadvantage, struggling to justify continued reimbursement.
"An outsourcing partner with expertise in health economics and outcomes research (HEOR), biostatistics, policy, and market access can help companies meet these HTA requirements efficiently," notes Hütter. "They provide the ‘qualified persons’ for pharmacovigilance that a company might not have the capacity to hire and manage on a local level."
Official Perspectives: Aligning Risk and Reward
The modern approach to outsourcing is not just about paying a vendor; it is about building a strategic partnership. The most effective engagements, according to industry experts, are built on outcome-based models where the service provider shares in both the risk and the reward.
This structure provides a triple-win:
- Financial Predictability: Companies move from fixed, high-overhead internal costs to variable, scalable costs.
- IP Continuity: The brand’s regulatory status remains in good standing, ensuring uninterrupted supply to patients.
- Scalability: When a company decides to enter or exit a specific market, the outsourcing partner provides the infrastructure to pivot immediately.
Janice Cassamajor, Director of Customer Success at Cencora, highlights the experience of a rapidly growing specialty pharma firm in the Asia-Pacific region. "The company was maintaining a portfolio of 10 brands across six therapeutic areas. By engaging a full-scope regulatory life cycle maintenance program, they were able to maintain high standards of compliance while significantly reducing operational overhead. This created the financial breathing room they needed to expand into additional international markets."
Implications for the Future of Pharma
The implication of this trend is clear: the divide between "core" and "legacy" will continue to blur. Companies that successfully treat their entire portfolio—from the newest breakthrough to the oldest legacy brand—as a dynamic, optimized asset will be the ones that survive the coming patent cliff.
1. The Strategy of "Reigniting" Value
Beyond cost reduction, there is a strategic opportunity to breathe new life into established brands. Through the support of outsourcing partners, firms can conduct:
- Secondary Indication Research: Using existing data to identify new patient populations.
- Fixed-Dose Combinations: Reformulating legacy drugs to improve patient adherence or efficacy.
- Market Expansion: Leveraging the partner’s regional expertise to bring a mature drug into underpenetrated markets.
2. The Talent Reallocation
Perhaps the most significant long-term impact is on internal culture. When internal regulatory and quality teams are no longer bogged down by the relentless grind of routine life cycle maintenance, they are free to engage in high-level strategic thinking. This shift is essential for firms that want to remain competitive in the face of rapid technological advancements in AI-driven drug discovery and personalized medicine.
3. Conclusion
In the current economic climate, maintaining the status quo is a recipe for decline. The "legacy" label should no longer be a reason to ignore an asset. By leveraging specialized outsourcing, pharmaceutical companies can ensure that their mature products continue to deliver essential value to patients while simultaneously fueling the innovation engine required for the next generation of life-saving therapies.
The future of pharmaceutical management lies in this dual focus: radical operational efficiency for the products of yesterday, and intense, unencumbered innovation for the products of tomorrow. Those who master this balance will not only survive the upcoming patent cliff—they will emerge from it more lean, more agile, and more profitable.
Disclaimer: This article is sponsored content. The information provided does not constitute legal advice and may contain marketing statements regarding Cencora. The reader is strongly encouraged to review available information related to the topics discussed in the article and to rely on their own experience and expertise in making decisions related thereto.
About the Author
